BioSpace News Archive

Business

Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors.

April 24, 2019
·
2 min read
BioCapital

HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients with Treatment Costs - April 23, 2019

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has launched a new fund to provide copayment and premium assistance to patients living with amyloidosis.

April 24, 2019
·
3 min read
Drug Development

Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients

Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

April 24, 2019
·
6 min read
Drug Development

MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients

MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

April 24, 2019
·
6 min read
Deals

Retrophin to Report First Quarter 2019 Financial Results

Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.

April 24, 2019
·
1 min read
Business

Novartis Poaches GSK Veteran as New Sandoz CEO

For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.

April 24, 2019
·
2 min read
·
Alex Keown
FDA

FDA gives AbbVie’s Skyrizi a Thumbs-Up for Plaque Psoriasis

Plaque psoriasis is the most common type of psoriasis, caused by overproduction of skin cells. This causes inflamed, red lesions called plaques.

April 24, 2019
·
3 min read
·
Mark Terry
Policy

Government Files Criminal Charges Against Opioid Distributor and Two Former Executives

The government said the executives and the company failed to comply with its legal obligation to report thousands of suspicious orders of controlled substances to the DEA.

April 24, 2019
·
3 min read
·
Alex Keown
Genetown

Fulcrum Therapeutics Licenses Failed GSK Drug for Possible Muscular Dystrophy Indication

Cambridge, Mass.-based Fulcrum Therapeutics just acquired a worldwide license with GlaxoSmithKline (GSK) to develop and commercialize losmapimod.

April 24, 2019
·
2 min read
·
Mark Terry
Pharm Country

Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth

Life sciences giant blamed the Medicare “doughnut hole” and increased competition for the blood thinner’s declining sales.

April 24, 2019
·
2 min read
·
Alex Keown